HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.